These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16787364)

  • 1. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
    Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
    Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
    Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
    Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives.
    Smith HM; Knox AJ; Zisterer DM; Lloyd DG; Meegan MJ
    Med Chem; 2007 Mar; 3(2):135-55. PubMed ID: 17348852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells.
    Meegan MJ; Hughes RB; Lloyd DG; Williams DC; Zisterer DM
    J Med Chem; 2001 Mar; 44(7):1072-84. PubMed ID: 11297454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
    Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
    J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
    Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
    Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.
    Tu Z; Li H; Ma Y; Tang B; Tian J; Akers W; Achilefu S; Gu Y
    Mol Cell Biochem; 2012 Jul; 366(1-2):111-22. PubMed ID: 22476901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
    Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells.
    Kraft KS; Ruenitz PC; Bartlett MG
    J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
    Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation.
    Kelly PM; Keely NO; Bright SA; Yassin B; Ana G; Fayne D; Zisterer DM; Meegan MJ
    Molecules; 2017 Aug; 22(9):. PubMed ID: 28858267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.
    Greschik H; Flaig R; Renaud JP; Moras D
    J Biol Chem; 2004 Aug; 279(32):33639-46. PubMed ID: 15161930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor.
    Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z
    J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches.
    Zhang L; Sedykh A; Tripathi A; Zhu H; Afantitis A; Mouchlis VD; Melagraki G; Rusyn I; Tropsha A
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):67-76. PubMed ID: 23707773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells.
    Meegan MJ; Barrett I; Zimmermann J; Knox AJ; Zisterer DM; Lloyd DG
    J Enzyme Inhib Med Chem; 2007 Oct; 22(5):655-66. PubMed ID: 18035834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
    Hoffman KL; Lerner SP; Smith CL
    Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents.
    Elghazawy NH; Engel M; Hartmann RW; Hamed MM; Ahmed NS; Abadi AH
    Future Med Chem; 2016; 8(3):249-56. PubMed ID: 26898104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
    Leblanc K; Sexton E; Parent S; Bélanger G; Déry MC; Boucher V; Asselin E
    Int J Oncol; 2007 Feb; 30(2):477-87. PubMed ID: 17203231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.
    Barrett I; Meegan MJ; Hughes RB; Carr M; Knox AJ; Artemenko N; Golfis G; Zisterer DM; Lloyd DG
    Bioorg Med Chem; 2008 Nov; 16(21):9554-73. PubMed ID: 18835176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.